Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome

In brief

The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.

Key facts

Study ID
NCT05364021
Run by
Longboard Pharmaceuticals
People needed
52
Starts
2022-03-03
Expected to finish
2023-11-20
Last updated by the study team
2024-11-08

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.